{"entity":{"id":"nct07002203","kind":"trial","name":"Personalized Neoantigen Peptide Vaccines for Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of Personalized Neoantigen Peptide Vaccine in advanced solid tumours, run by Seqker Biosciences, Inc., now recruiting.","summary":"Personalized Neoantigen Peptide Vaccines for Solid Tumors is a phase 1/2 interventional study registered as NCT07002203 by Seqker Biosciences, Inc., with 10 participants planned, started 2024-03-01 and due to reach its primary completion in 2027-08. Interventions recorded: Personalized Neoantigen Peptide Vaccine.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07002203","url":"https://clinicaltrials.gov/study/NCT07002203"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07002203","phase":"1/2","setting":"A Phase Ib Clinical Study of Personalized Neoantigen Peptide Vaccines for Solid Tumors","sponsor":"Seqker Biosciences, Inc.","enrolled":10,"outcomes":[]},"route":"/trials/nct07002203/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}]}}